Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients

References

• KawasakiRYasudaMSongSJThe prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysisOphthalmology2010117592192720110127
   PubMed Web of Science ®Google Scholar
• KlaverCCAssinkJJvan LeeuwenRIncidence and progression rates of age-related maculopathy: the Rotterdam StudyInvest Ophthalmol Vis Sci200142102237224111527936
   PubMed Web of Science ®Google Scholar
• KleinRKleinBECruickshanksKJThe prevalence of age-related maculopathy by geographic region and ethnicityProg Retin Eye Res199918337138910192518
   PubMed Web of Science ®Google Scholar
• KleinRPetoTBirdAVannewkirkMRThe epidemiology of age-related macular degenerationAm J Ophthalmol2004137348649515013873
   PubMed Web of Science ®Google Scholar
• WongTYWongTChakravarthyUThe natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysisOphthalmology2008115111612617675159
   PubMed Web of Science ®Google Scholar
• WongCWYanagiYLeeWKAge-related macular degeneration and polypoidal choroidal vasculopathy in AsiansProg Retin Eye Res20165310713927094371
   PubMed Web of Science ®Google Scholar
• FerrisFLFineSLHymanLAge-related macular degeneration and blindness due to neovascular maculopathyArch Ophthalmol198410211164016426208888
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• GasperiniJLFawziAAKhondkaryanABevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisationBr J Ophthalmol2012961142021791509
   PubMed Web of Science ®Google Scholar
• EghøjMSSørensenTLTachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumabBr J Ophthalmol2012961212321733918
   PubMed Web of Science ®Google Scholar
• KrebsIGlittenbergCAnsari-ShahrezaeiSHagenSSteinerIBinderSNon-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degenerationBr J Ophthalmol201397111443144623966368
   PubMed Web of Science ®Google Scholar
• PapadopoulosNMartinJRuanQBinding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis201215217118522302382
   PubMed Web of Science ®Google Scholar
• RakicJMLambertVDevyLPlacental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularizationInvest Ophthalmol Vis Sci20034473186319312824270
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology20091161576519118696
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• WaldsteinSMSimaderCStaurenghiGMorphology and visual acuity in aflibercept and ranibizumab therapy for neovascular age-related macular degeneration in the VIEW trialsOphthalmology201612371521152927157149
   PubMed Web of Science ®Google Scholar
• HirakataTFujinamiKWatanabeKSasakiMNodaTAkiyamaKOne-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvementClin Ophthalmol20161096997727307700
   PubMed Web of Science ®Google Scholar
• RicciFParravanoMRegineFAflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapyEye20163081077108327229701
   PubMed Web of Science ®Google Scholar
• SaraoVParravanoMVerittiDAriasLVaranoMLanzettaPIntravitreal aflibercept for choroidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapyRetina201636477077726398691
   PubMed Web of Science ®Google Scholar
• YamamotoAOkadaAANakayamaMYoshidaYKobayashiHOne-year outcomes of a treat-and-extend regimen of aflibercept for exudative age-related macular degenerationOphthalmologica2017237313914428259869
   PubMed Web of Science ®Google Scholar
• EssexRWNguyenVWaltonRTreatment patterns and visual outcomes during the maintenance phase of treat-and-extend therapy for age-related macular degenerationOphthalmology2016123112393240027554034
   PubMed Web of Science ®Google Scholar
• Seguin-GreensteinSLightmanSTomkins-NetzerOA meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with afliberceptJ Ophthalmol20162016409585227042342
   PubMed Web of Science ®Google Scholar
• ChatziralliINicholsonLVrizidouEPredictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly afliberceptOphthalmology201612381762177027289179
   PubMed Web of Science ®Google Scholar
• Pinheiro-CostaJCostaJMBeatoJNSwitch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practiceOphthalmologica20152333–415516125896317
   PubMed Web of Science ®Google Scholar
• HataMTsujikawaAMiyakeMTwo-year visual outcome of ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol2015253222122724961698
   PubMed Web of Science ®Google Scholar
• KawashimaYOishiATsujikawaAEffects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol201525391471147725391986
   PubMed Web of Science ®Google Scholar
• MiuraMIwasakiTGotoHIntravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxisClin Ophthalmol201371591159523966764
   PubMedGoogle Scholar
• ChoHJKimKMKimHSIntravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathyAm J Ophthalmol20161651626921806
   PubMed Web of Science ®Google Scholar
• StangosANGandhiJSNair-SahniJHeimannHPournarasCJHardingSPPolypoidal choroidal vasculopathy masquerading as neo-vascular age-related macular degeneration refractory to ranibizumabAm J Ophthalmol2010150566667320719300
   PubMed Web of Science ®Google Scholar
• JørstadØKFaberRTMoeMCTwo-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocolActa Ophthalmol201795546046328556485
   PubMed Web of Science ®Google Scholar
• AzumaKObataRNomuraYTanXTakahashiHYanagiYAngiographic findings of ranibizumab-resistant polypoidal choroidal vasculopathy after switching to a treat-and-extend regimen with intravitreal afliberceptRetina201636112158216527258669
   PubMed Web of Science ®Google Scholar
• ChoHJKimHSJangYSEffects of choroidal vascular hyper-permeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathyAm J Ophthalmol201315661192120024011522
   PubMed Web of Science ®Google Scholar
• JirarattanasopaPOotoSNakataIChoroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathyInvest Ophthalmol Vis Sci20125373663367222570352
   PubMed Web of Science ®Google Scholar
• KoizumiHKanoMYamamotoASubfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month resultsOphthalmology2016123361762426686967
   PubMed Web of Science ®Google Scholar
• MiyakeMTsujikawaAYamashiroKChoroidal neovascularization in eyes with choroidal vascular hyperpermeabilityInvest Ophthalmol Vis Sci20145553223323024781946
   PubMed Web of Science ®Google Scholar
• KohALeeWKChenLJEVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathyRetina20123281453146422426346
   PubMed Web of Science ®Google Scholar
• SaitoMKanoMItagakiKIseSImaizumiKSekiryuTSubfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injectionJpn J Ophthalmol2016601354126350229
   PubMed Web of Science ®Google Scholar
• BurnhamKPAndersonDRInferenceMMultimodel inference understanding AIC and BIC in model selectionSociol Methods Res2004332261304
   Web of Science ®Google Scholar
• MallowsCLSome comments on CPTechnometrics1973154661675
   Web of Science ®Google Scholar
• TibshiraniRJTaylorJDegrees of freedom in lasso problemsAnn Stat201240211981232
   Web of Science ®Google Scholar
• ArcinueCAMaFBarteselliGSharpstenLGomezMLFreemanWROne-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degenerationAm J Ophthalmol2015159342643625461263
   PubMed Web of Science ®Google Scholar
• SinghRPSrivastavaSKEhlersJPA single-arm, investigator-initiated study of the efficacy, safety, and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration previously treated with ranibizumab or bevacizumab (ASSESS study): 12-month analysisClin Ophthalmol201591759176626445522
   PubMedGoogle Scholar
• BergKHadzalicEGjertsenIRanibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year resultsOphthalmology20161231515926477842
   PubMed Web of Science ®Google Scholar
• KvannliLKrohnJSwitching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degenerationActa Ophthalmol201795767868228139082
   PubMed Web of Science ®Google Scholar
• AlmuhtasebHJohnstonRLTalksJSLoteryAJSecond-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users GroupEye201731111582158828622328
   PubMed Web of Science ®Google Scholar
• MorimotoMMatsumotoHMimuraKAkiyamaHTwo-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol2017255101891189728669041
   PubMed Web of Science ®Google Scholar
• ChoMBarbazettoIAFreundKBRefractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathyAm J Ophthalmol200914878170
   Web of Science ®Google Scholar
• HikichiTHiguchiMMatsushitaTResults of 2 years of treatment with as-needed ranibizumab reinjection for polypoidal choroidal vasculopathyBr J Ophthalmol201397561762123428984
   PubMed Web of Science ®Google Scholar
• OishiAKojimaHMandaiMComparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study resultsAm J Ophthalmol2013156464465123876867
   PubMed Web of Science ®Google Scholar
• OishiAMiyamotoNMandaiMLAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathyOphthalmology201412151151115224484991
   PubMed Web of Science ®Google Scholar
• OishiATsujikawaAYamashiroKOne-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcomeAm J Ophthalmol2015159585386025634529
   PubMed Web of Science ®Google Scholar
• HikichiTKitameiHShioyaSPrognostic factors of 2-year outcomes of ranibizumab therapy for polypoidal choroidal vasculopathyBr J Ophthalmol201599681782225480464
   PubMed Web of Science ®Google Scholar
• WaldsteinSMWrightJWarburtonJMargaronPSimaderCSchmidt-ErfurthUPredictive value of retinal morphology for visual acuity outcomes of different ranibizumab treatment regimens for neovascular AMDOphthalmology20161231606926481821
   PubMed Web of Science ®Google Scholar
• FreundKBZweifelSAEngelbertMDo we need a new classification for choroidal neovascularization in age-related macular degeneration?Retina20103091333134920924258
   PubMed Web of Science ®Google Scholar
• SharmaSTothCADanielEMacular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trialsOphthalmology2016123486587526783095
   PubMed Web of Science ®Google Scholar
• KoizumiHKanoMYamamotoAShort-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degenerationAm J Ophthalmol2015159462763325555799
   PubMed Web of Science ®Google Scholar
• NishideTHayakawaNShibuyaEYagiYMizukiNChoroidal thickness is affected by many factors which may change the effect of ranibizumab: author’s responseGraefes Arch Clin Exp Ophthalmol2014252584985024562412
   PubMed Web of Science ®Google Scholar
• SaitoMKanoMItagakiKOguchiYSekiryuTSwitching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumabRetina201434112192220125077530
   PubMed Web of Science ®Google Scholar
• StewartMWRosenfeldPJPredicted biological activity of intravitreal VEGF TrapBr J Ophthalmol200892566766818356264
   PubMed Web of Science ®Google Scholar
• FerraraNDamicoLShamsNLowmanHKimRDevelopment of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degenerationRetina200626885987017031284
   PubMed Web of Science ®Google Scholar
• LoweJAraujoJYangJRanibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivoExp Eye Res200785442543017714704
   PubMed Web of Science ®Google Scholar
• HoodJDMeiningerCJZicheMGrangerHJVEGF upregulates ecNOS message, protein, and NO production in human endothelial cellsAm J Physiol19982743 Pt 2H1054H10589530221
   PubMed Web of Science ®Google Scholar